Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
8420
Trial Sponsor
Clinical Trial Start Date
2004
0Study Completion Date
2006
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Interventional Trial Phase
Phase 30
Official Name
Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer0
Last Updated
August 23, 2007
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Outcomes Assessor0
Participant0
Care Provider0
Investigator0
Study summary
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
